Last reviewed · How we verify

brimonidine topical gel 0.33% & SOC

Wake Forest University Health Sciences · FDA-approved active Small molecule

brimonidine topical gel 0.33% & SOC is a Alpha-2 adrenergic agonist Small molecule drug developed by Wake Forest University Health Sciences. It is currently FDA-approved for Persistent facial erythema associated with rosacea. Also known as: Mirvaso.

Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces redness when applied topically to the skin.

Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces redness when applied topically to the skin. Used for Persistent facial erythema associated with rosacea.

At a glance

Generic namebrimonidine topical gel 0.33% & SOC
Also known asMirvaso
SponsorWake Forest University Health Sciences
Drug classAlpha-2 adrenergic agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Brimonidine selectively binds to alpha-2 adrenergic receptors on vascular smooth muscle cells, causing vasoconstriction that reduces blood flow to the treated area. This mechanism decreases the appearance of facial erythema (redness) associated with conditions like rosacea. The gel formulation allows for localized topical delivery with minimal systemic absorption.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about brimonidine topical gel 0.33% & SOC

What is brimonidine topical gel 0.33% & SOC?

brimonidine topical gel 0.33% & SOC is a Alpha-2 adrenergic agonist drug developed by Wake Forest University Health Sciences, indicated for Persistent facial erythema associated with rosacea.

How does brimonidine topical gel 0.33% & SOC work?

Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces redness when applied topically to the skin.

What is brimonidine topical gel 0.33% & SOC used for?

brimonidine topical gel 0.33% & SOC is indicated for Persistent facial erythema associated with rosacea.

Who makes brimonidine topical gel 0.33% & SOC?

brimonidine topical gel 0.33% & SOC is developed and marketed by Wake Forest University Health Sciences (see full Wake Forest University Health Sciences pipeline at /company/wake-forest-university-health-sciences).

Is brimonidine topical gel 0.33% & SOC also known as anything else?

brimonidine topical gel 0.33% & SOC is also known as Mirvaso.

What drug class is brimonidine topical gel 0.33% & SOC in?

brimonidine topical gel 0.33% & SOC belongs to the Alpha-2 adrenergic agonist class. See all Alpha-2 adrenergic agonist drugs at /class/alpha-2-adrenergic-agonist.

What development phase is brimonidine topical gel 0.33% & SOC in?

brimonidine topical gel 0.33% & SOC is FDA-approved (marketed).

What are the side effects of brimonidine topical gel 0.33% & SOC?

Common side effects of brimonidine topical gel 0.33% & SOC include Erythema (rebound redness), Pruritus, Skin irritation, Pallor.

What does brimonidine topical gel 0.33% & SOC target?

brimonidine topical gel 0.33% & SOC targets Alpha-2 adrenergic receptor and is a Alpha-2 adrenergic agonist.

Related